---
symbol: "LLY"
name: "Eli Lilly"
date: 2026-10-29
change_pct: 5.591547123245411
direction: "up"
event_type: "guidance"
url: "https://perplo.app/why/LLY/2026-10-29"
updated_at: 2026-10-29T15:07:15.676Z
---

# Why Eli Lilly (LLY) rose 5.59% on October 29, 2026

Eli Lilly (LLY) rose 5.59% on October 29, 2026 — Raised outlook sends Eli Lilly to record high.

## What happened

Healthcare and biotech rallied, with peers up a median 3.8%, and Eli Lilly hit a record high at the open after raising its outlook.

## Why it moved

The sector-wide bid drove most of the move, and Lilly's outlook raise, backed by surging Zepbound and Mounjaro demand, added extra support that pushed it past the group's pace.

## Why it matters

Lilly is the marquee name in the Healthcare & Biotech theme, where GLP-1 adoption has carried the sector. This move is a group-wide bid with Lilly's guidance riding on top.

## What would break the thesis

If management qualifies the raise or the market treats it as fully priced, the premium over the group should close. A broader biotech cooling would also weigh on it.

## Sources

- [ELI LILLY SHARES HIT RECORD HIGH AT THE OPEN ON OUTLOOK RAISE](https://t.me/marketfeed/1066964) — MarketFeed
- [Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again](https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html) — CNBC
- [Lilly raises outlook for third time this year as Zepbound sales soar](https://www.marketwatch.com/story/lilly-raises-outlook-for-third-time-this-year-as-zepbound-sales-soar-6d987407?mod=mw_rss_topstories) — MarketWatch

---

Trade LLY perpetual futures 24/7 onchain: https://perplo.app/asset/LLY